Wixela Dosing and Usage
Wixela (fluticasone propionate/formoterol fumarate) is dosed as 1 inhalation twice daily (approximately 12 hours apart) for both asthma and COPD, with specific strength selection based on disease severity and patient age. 1
Asthma Dosing
Adults and Adolescents (≥12 years)
- Starting dose: 1 inhalation twice daily of Wixela 100/50,250/50, or 500/50 based on:
- Previous ICS dose
- Current symptom control
- Exacerbation risk 1
- Maximum dose: Wixela 500/50 twice daily 1
- Onset: Improvement may occur within 30 minutes, but maximum benefit typically requires 1 week or longer 1
- Dose adjustment: If inadequate response after 2 weeks, consider stepping up to higher strength 1
Children (4-11 years)
- Fixed dose: 1 inhalation of Wixela 100/50 twice daily only 1
- This is the only approved strength for this age group
COPD Dosing
For all COPD patients: 1 inhalation of Wixela 250/50 twice daily 1
- This is the only approved strength for COPD—higher strengths have not demonstrated efficacy advantage 1
- Indicated for maintenance treatment of airflow obstruction and reduction of exacerbations in patients with exacerbation history 1
Critical Administration Points
Route: Oral inhalation only 1
Post-inhalation care: Rinse mouth with water without swallowing to reduce oropharyngeal candidiasis risk 1
Rescue therapy: Use short-acting beta2-agonist (SABA) for acute symptoms between doses—never use additional LABA 1
Frequency limitation: More than 1 inhalation twice daily is NOT recommended due to increased adverse effects with higher salmeterol doses 1
Important Contraindications
- NOT for acute bronchospasm relief in either asthma or COPD 1
- Never use as monotherapy without the ICS component
- Patients on Wixela should not use additional LABA for any reason 1
Clinical Context
Wixela Inhub is a generic equivalent of Advair Diskus, containing fluticasone propionate (ICS) and formoterol fumarate (LABA) 2. The formoterol component provides rapid onset of action compared to salmeterol-containing products 3. The device demonstrates comparable in vitro performance and bioequivalence to the reference product across all patient-relevant flow rates 3.
The combination ICS/LABA approach aligns with current guidelines recommending combination therapy for moderate-to-severe persistent asthma 4 and for COPD patients with exacerbation history 5. The fixed-dose combination ensures patients receive anti-inflammatory therapy with each bronchodilator dose, addressing the critical safety concern of LABA monotherapy 6, 7.